Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncogene. 2006 Feb 16;25(7):1042-52.

IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1.

Author information

1
Department of Biomedical Genetics Univeristy of Rochester, Rochester, NY 14642, USA. yin_sun@urmc.rochester.edu

Abstract

Synovial sarcoma is an aggressive soft tissue tumor characterized by a specific chromosomal translocation between chromosome 18 and X. This translocation can generate a fusion transcript encoding SYT-SSX1, a transforming oncoprotein. We present evidence that SYT-SSX1 induces insulin-like growth factor II expression in fibroblast cells. SYT-SSX2, a fusion also frequently found in synovial sarcoma, is necessary for maintaining Igf2 expression in the synovial sarcoma cell line, and the increased IGF2 synthesis protects cells from anoikis and is required for tumor formation in vivo. We also found a loss of imprinting (LOI) for Igf2 in a limited number of primary synovial sarcomas despite demethylation of CpG dinucleotides critical for maintaining imprinting. These findings suggest that inhibition of the IGF2/IGF1-R signaling pathway may represent a significant therapeutic modality for treating synovial sarcoma.

PMID:
16247461
DOI:
10.1038/sj.onc.1209143
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center